AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$KURA

Bair Teresa Brophy sold $398K of KURA

Bair Teresa Brophy (Chief Legal Officer) sold 31,487 shares of Kura Oncology, Inc. (KURA) at $12.63 ($0.40M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bair Teresa Brophy
Published Aug 21, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KURA
Bearish
medium confidence
Mentioned
$KURA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KURABearishLow
01

Why it matters

The disclosure provides fresh data on insider holdings, useful for short-term traders.

02

Market read

Primary insider transaction; modest relevance for short-term price action.

03

What to watch

The insider retains a sizable stake, indicating continued confidence.

Relevance 3/10Novelty 6/10Timing: post-market 2026-08-19

Background

Kura Oncology filed a Form 4 reporting an insider sale under a 10b5-1 plan.

Company-level read

Ticker impact

$KURABearishMedium confidence
Context

Form 4 disclosed Chief Legal Officer sold 31,487 shares for $397,680, reducing her stake to 195,444 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size is modest relative to market cap, but insider sales often trigger short-term sell pressure.

Market effects

Sector

Minimal impact on the broader oncology biotech sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Officer
    Bair Teresa Brophy

    Chief Legal Officer of Kura Oncology.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KURA insider trading history →

Related articles

OCT 13
$KURAMedAI 8/10

Some rats regained normal blood sugar for a month after an experimental diabetes treatment stopped

Caspian Therapeutics and Kura Oncology (KURA) will discuss the development strategy for KO-7246, an oral menin inhibitor for diabetes, in a webcast. Preclinical findings showed improved glucose control and beta cell expansion in animal models. Caspian plans to conduct a Phase 1 clinical trial to assess safety and insulin production. Kura owns half of Caspian and retains research collaboration rights.

stocktitan.net2 min
SEP 29
$KURAMedAI 8/10

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

Caspian Therapeutics and Kura Oncology presented preclinical data on KO-7246, a menin inhibitor, showing potential for diabetes treatment. KO-7246 regenerated β-cell mass and controlled glycemic levels in Type 1 and Type 2 diabetes models. Caspian aims to develop KO-7246 as a best-in-class therapy, with an investor event scheduled for October 13, 2026.

finance.yahoo.com3 min
SEP 9
$KURAMed

KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil

Kura Oncology (KURA) launched Caspian Therapeutics, a spin-off focused on menin inhibition therapies for diabetes and cardiometabolic diseases. Kura retains 50% ownership. The company's P/S ratio is 14.3x, above its historical median of 10.6x, reflecting growth expectations despite unprofitability. Insider activity shows net selling, while guru investors have mixed positions.

gurufocus.com2 min